Chinanews.com, Beijing, December 15 (Ma Shuaisha) Centralized procurement to promote the replacement of generic drugs-a press conference on changes in the use of unselected original research drugs in centralized procurement was held in Beijing on the 15th.

The data shows that the average price of drugs for the first five batches of countries to organize centralized drug purchases has fallen by more than 50%.

When introducing the effectiveness of centralized drug procurement, experts at the conference said that centralized procurement has optimized the structure of drug use, improved the availability of drugs, and reduced the burden of medication for patients, which will force the realization of the "patent cliff".

　　Jiang Changsong, an associate researcher of the National Institutes of Medical Security of Capital Medical University, introduced the Chinese prescription drug market before centralized procurement.

He pointed out that, unlike developed countries, China's original research drugs and generic drugs accounted for more than 60% of the amount before centralized procurement, while the amount of patented drugs did not account for a high proportion.

This shows that China did not form an effective patent cliff in the past. After the expiration of drug patents, the prices of original research drugs and generic drugs have not fallen.

　　In his view, the current volume procurement model in China is the most effective drug procurement model in line with China's national conditions, that is, medical insurance purchases on behalf of patients, enterprises compete fairly, and return to market mechanisms.

This has not only opened up the blockages in the drug circulation links such as bidding, procurement, use, payment, and payment, and reduced transaction costs, but also converted the agency relationship, and promoted doctors' prescription rights for drugs in line with international standards.

　　Regarding the current results of centralized drug procurement, Liu Wenxin, director of the Technical Standards Department of the China Medical Insurance Research Association, said that in recent years, the scope of centralized drug procurement organized by the state has continued to expand. The average price of the first five batches of state-organized centralized drug procurement has fallen by more than 50%. , The price of the latest batch of special insulin purchases dropped by an average of about 48%.

　　The recently released "China Medical Insurance Drug Administration Reform Progress and Effectiveness Blue Book" also shows that there are 15 types of diabetes medications, and the amount involved accounts for more than 60% of the oral hypoglycemic drug market, and the average price is reduced by 69% after centralized procurement.

There are 4 kinds of drugs for hyperlipidemia and high cholesterol, the amount involved accounts for more than 80% of the market size of lipid-lowering drugs, and the average price is reduced by 81% after the collection.

　　In this regard, Liu Wenxin pointed out that the post-collection drug purchases showed a pattern of "two reductions and one increase." The "substitution effect" of the drug is obvious; the price of medicines shows the law of "three prices", the price of selected generic drugs has fallen most significantly, the price of original research drugs has fallen along with it, and the prices of unselected generic drugs have also decreased simultaneously.

"The centralized procurement policy has promoted the optimization of the drug use structure and reduced the burden of patients on drug use."

　　Hu Xin, director of the Department of Pharmacy of Beijing Hospital, also said that centralized procurement has greatly improved the availability of medicines, reduced the burden of medication, promoted the development of "high-end preparations, green raw materials", and forced the realization of the "patent cliff".

Centralized procurement has also led to an overall decline in the prices of drugs of the same disease, freeing up space for exploring outpatient coordination and increasing the proportion of reimbursements for chronic diseases and serious illnesses.

　　Talking about the role of centralized procurement in reducing costs and promoting R&D, Hu Xin pointed out that it is "moisture" rather than corporate profits. Data from key companies shows that sales personnel of selected products have been reduced by an average of 49%, and the proportion of sales expenses in sales has changed from 40% dropped to 5%-10%.

This has promoted the improvement of the ecology of the pharmaceutical industry and the virtuous circle of Chinese drug research and development.

(Finish)